Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing

BMC Cardiovascular Disorders

Volumn 16, Issue 1, 2016, Pages

  Yang, Qian ^a,b   Qi, Xiaoyong ^a,b   Dang, Yi ^b   Li, Yingxiao ^b   Song, Xuelian ^b   Hao, Xiao ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Atorvastatin; Atrial fibrillation; Atrial remodeling; Myeloperoxidase

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL L TYPE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; L TYPE CALCIUM CHANNEL ALPHA1C; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIAL EFFECTIVE REFRACTORY PERIOD; ATRIAL FIBRILLATION INDUCIBILITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART ATRIUM PACING; HEART ATRIUM REMODELING; HISTOPATHOLOGY; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SHAM PROCEDURE; WESTERN BLOTTING; ANIMAL; ATRIAL FIBRILLATION; DIAGNOSTIC IMAGING; DISEASE MODEL; ELECTROCARDIOGRAPHY; GENETICS; HEART ATRIUM; HEART ATRIUM FUNCTION; HEART PACING; HEART RATE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RABBITS AND HARES;

ANIMALS; ATORVASTATIN CALCIUM; ATRIAL FIBRILLATION; ATRIAL FUNCTION, RIGHT; ATRIAL REMODELING; BLOTTING, WESTERN; CARDIAC PACING, ARTIFICIAL; DISEASE MODELS, ANIMAL; DNA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ATRIA; HEART RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PEROXIDASE; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84975744393     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0301-8     Document Type: Article

References (43)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-98.
2. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47.
3. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325.
4. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335-45.
5. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470-4.
6. Friedrichs K, Baldus S, Klinke A. Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO. Front Physiol. 2012;3:214.
7. Li SB, Yang F, Jing L, Ma J, Jia YD, Dong SY, et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J Investig Med. 2013;61:722-7.
8. Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal. 2014;20:1268-85.
9. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013;28:7-18.
10. Yang Q, Qi X, Li Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2014;14:99.
11. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313-9.
12. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74:75-84.
13. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation. 2011;124:1107-17.
14. Li J, Xia W, Feng W, Qu X. Effects of rosuvastatin on serum asymmetric dimethylarginine levels and atrial structural remodeling in atrial fibrillation dogs. Pacing Clin Electrophysiol. 2012;35:456-64.
15. Ndrepepa G, Braun S, Schomig A, Kastrati A. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol. 2011;100:327-33.
16. Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis. 2010;210:194-8.
17. Yu J, Li W, Li Y, Zhao J, Wang L, Dong D, et al. Activation of beta(3)-adrenoceptor promotes rapid pacing-induced atrial electrical remodeling in rabbits. Cell Physiol Biochem. 2011;28:87-96.
18. Fu H, Liu C, Li J, Zhou C, Cheng L, Liu T, et al. Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiol J. 2013;20:59-67.
19. Zhao Y, Gu TX, Zhang GW, Liu HG, Wang C. Losartan affects the substrate for atrial fibrillation maintenance in a rabbit model. Cardiovasc Pathol. 2013;22:383-8.
20. Nakatani Y, Nishida K, Sakabe M, Kataoka N, Sakamoto T, Yamaguchi Y, et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:582-8.
21. He X, Gao X, Peng L, Wang S, Zhu Y, Ma H, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin ii type 1 receptor-specific arkadia-mediated downregulation of smad7. Circ Res. 2011;108:164-75.
22. Weiss JN, Qu Z, Chen PS, Lin SF, Karagueuzian HS, Hayashi H, et al. The dynamics of cardiac fibrillation. Circulation. 2005;112:1232-40.
23. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124:2264-74.
24. Cui Q, Zhang W, Wang H, Sun X, Yang H, Meng X, et al. Left and right atrial size and the occurrence predictors in patients with paroxysmal atrial fibrillation. Int J Cardiol. 2008;130:69-71.
25. Marchese P, Bursi F, Delle Donne G, Malavasi V, Casali E, Barbieri A, et al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr. 2011;12:214-21.
26. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-9.
27. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-4.
28. Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol. 2010;159:1584-94.
29. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci. 2008;65:1489-508.
30. de Jong S, van Veen TA, de Bakker JM, Vos MA, van Rijen HV. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol. 2011;57:522-35.
31. Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol. 2008;45:742-53.
32. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun. 2005;331:442-51.
33. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-75.
34. Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus-Santos JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:547-54.
35. Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol. 2010;145:438-43.
36. Lin Q, Jia L, Sun Y. A pilot study of circulating ppar-gamma receptor protein in elderly patients with atrial fibrillation. Arch Med Sci. 2012;8:471-6.
37. Chen X, Bing Z, He J, Jiang L, Luo X, Su Y, et al. Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. Clin Cardiol. 2009;32:337-45.
38. Liu T, Zhao H, Li J, Korantzopoulos P, Li G. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiovasc Ther. 2014;32:178-83.
39. Gu J, Liu X, Wang QX, Guo M, Liu F, Song ZP, et al. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. J Mol Cell Cardiol. 2013;65:1-8.
40. Chao TF, Leu HB, Huang CC, Chen JW, Chan WL, Lin SJ, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol. 2012;156:199-202.
41. Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H, et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma. Eur J Pharmacol. 2010;649:255-62.
42. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa Y, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007;100:1442-51.
43. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12:230-43.